ECM
ASMB icon

Endurant Capital Management’s Assembly Biosciences ASMB Stock Holding History

Endurant Capital Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-792
Closed -$430K – 71
2017
Q4 		$430K Buy
+792
New +$359K 0.13% 70

Other funds holding ASMB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Endurant Capital Management's ASMB Position: Q1 2018 in Review

Endurant Capital Management sold out of Assembly Biosciences (ASMB) in Q1 2018, closing a stake of 792 shares — an estimated $430K sold.

Endurant Capital Management first reported a position in ASMB in Q4 2017 and held it in 1 quarter. The position peaked at $430K in Q4 2017. 107 funds tracked by Wall St. Rank hold ASMB as of Q1 2018.

  • Endurant Capital Management reported no remaining Assembly Biosciences position as of Q1 2018 after selling out during the quarter.
  • Endurant Capital Management sold 792 Assembly Biosciences shares in Q1 2018, an estimated $430K.
  • Endurant Capital Management first reported a position in Assembly Biosciences in Q4 2017 and held it in 1 quarter.
  • Endurant Capital Management's Assembly Biosciences position peaked at $430K in Q4 2017.
  • 107 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2018.

Based on Endurant Capital Management's 13F filing for Q1 2018, filed 15 May 2018.